Director of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) sells $306,800.00 in stock
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) chief Donald A. Denkhaus sold 20,000 shares of the company in a trade that took place on Wednesday, September 14. The stock was sold at an average price of $15.34, for a total transaction of $306,800.00. Following completion of the transaction, the administrator now directly owns 297,666 shares of the company, valued at $4,566,196.44. The transaction was disclosed in a filing with the SEC, which is available on the SEC’s website.
Performance of Catalyst Pharmaceuticals shares
The NASDAQ CPRX fell $1.90 on Thursday, hitting $13.62. The stock recorded a trading volume of 8,973,919 shares, compared to an average volume of 1,812,987 shares. The company has a 50-day moving average of $11.96 and a 200-day moving average of $9.03. The company has a market capitalization of $1.40 billion, a price-earnings ratio of 27.22 and a beta of 1.31. Catalyst Pharmaceuticals, Inc. has a 52-week low of $4.81 and a 52-week high of $17.22.
A Wall Street analyst gives his opinion
Several research companies have recently commented on CPRX. Roth Capital downgraded Catalyst Pharmaceuticals shares from a “buy” rating to a “neutral” rating and raised its price target for the stock from $10.00 to $15.50 in a Wednesday, August 24 report . Truist Financial raised its price target on Catalyst Pharmaceuticals shares from $12.00 to $17.00 and gave the stock a “buy” rating in a Thursday, August 11 report. HC Wainwright raised its price target on Catalyst Pharmaceuticals shares from $12.00 to $18.00 and gave the stock a “buy” rating in a Thursday, Aug. 11 research note. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong buy” rating in a Monday, August 8 research rating. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned the company a strong buy rating. According to MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average target price of $14.81.
Catalyst Pharmaceuticals Institutional Trading
Several institutional investors and hedge funds have recently changed their positions in CPRX. FMR LLC increased its position in Catalyst Pharmaceuticals shares by 24.2% during the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company valued at $30,000 after purchasing an additional 822 shares last quarter. Point72 Hong Kong Ltd increased its position in Catalyst Pharmaceuticals shares by 84.3% during the 4th quarter. Point72 Hong Kong Ltd now owns 5,932 shares of the biopharmaceutical company valued at $40,000 after buying 2,713 additional shares last quarter. Covestor Ltd increased its position in Catalyst Pharmaceuticals shares by 768.0% during the first quarter. Covestor Ltd now owns 4,878 shares in the biopharmaceutical company valued at $40,000 after buying an additional 4,316 shares last quarter. Quantbot Technologies LP purchased a new equity stake in Catalyst Pharmaceuticals during Q1 for $62,000. Finally, Quantamental Technologies LLC purchased a new equity stake in Catalyst Pharmaceuticals during Q2 for $72,000. Hedge funds and other institutional investors hold 74.16% of the company’s shares.
About Catalyst Pharmaceuticals
(Get a rating)
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, is focused on developing and commercializing therapies for people with rare, debilitating, neuromuscular and chronic neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablet for the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Catalyst Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off… and Catalyst Pharmaceuticals was not on the list.
While Catalyst Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here